Technology | AI | Healthcare

Danaher Corporation to Acquire Masimo Corporation

$9.9B Masimo deal strengthens diagnostics and real-time care.

hospital monitor displaying vital signs: heart rate, blood pressure, temperature, and pulse oximetry, highlighting advanced medical technology in patient care

Written By: BOSS Editorial

Published: February 17, 2026

Reading Time: 5 minutes

Share this story

The healthcare industry is moving rapidly toward connected devices, continuous monitoring, and AI-enabled decision support. As hospitals and health systems seek more integrated and predictive care models, technology platforms that combine diagnostics, analytics, and real-time data are becoming increasingly valuable.

Against this backdrop, Danaher Corporation’s planned acquisition of Masimo Corporation represents a major strategic investment in the future of digital and precision healthcare. The transaction brings together advanced sensing technologies, large-scale clinical data, and AI-enabled diagnostics within a unified platform.

Acquisition Overview

Danaher has agreed to acquire Masimo for $180 per share in cash, valuing the transaction at approximately $9.9 billion. The deal is expected to close in the second half of 2026, subject to regulatory and shareholder approval. Masimo is best known for its pulse oximetry systems and advanced sensor technologies used in critical and acute care environments. Its platforms collect high-resolution physiologic data, including oxygen saturation, heart rate, and respiratory indicators, in real time. These technologies play a central role in clinical decision-making, enabling earlier detection of patient deterioration and supporting continuous monitoring in hospitals and remote care settings.

According to MedTech Dive, following the acquisition, Masimo will operate as a standalone business and brand within Danaher’s Diagnostics portfolio. The deal is intended to strengthen Danaher’s acute care and patient monitoring capabilities, particularly through Masimo’s advanced sensor and AI-enabled technologies. Masimo’s board reviewed multiple partnership and acquisition options before selecting Danaher as the preferred buyer. Chair Michelle Brennan said the company determined the transaction offered the strongest long-term value for stakeholders. Masimo will join Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics within Danaher. The company is expected to deliver high-single-digit core revenue growth and generate more than $530 million in EBITDA by 2027, contributing to faster growth across Danaher’s diagnostics segment.

Option 2 (17)

Expanding AI-Enabled Diagnostics

Masimo’s technology portfolio includes AI-enabled and algorithm-driven monitoring tools designed to improve signal accuracy and reduce false alarms. These systems enhance the reliability of physiologic measurements in complex clinical environments. When combined with Danaher’s diagnostics infrastructure, these capabilities create opportunities to connect laboratory data with continuous patient monitoring. This integration supports more unified clinical workflows, where diagnostics, monitoring, and analytics operate within a shared ecosystem. As a result, clinicians gain faster access to actionable insights at the point of care, improving response times and care coordination.

By bringing Masimo into its Diagnostics segment, Danaher gains access to large-scale physiologic datasets generated across diverse care settings. These datasets can be used to develop predictive models, risk stratification tools, and clinical decision-support systems. Over time, this foundation may enable advanced applications in population health management, hospital automation, and personalized medicine. For clinicians managing high-risk and complex patients, these tools support earlier intervention and more targeted treatment strategies.

Rapid Growth in AI Medical Devices

Market forecasts highlight strong momentum behind AI-enabled healthcare technologies. A new GlobeNewswire report projects rapid expansion in the global AI in medical devices market, growing from about $22 billion in 2024 to approximately $886 billion by 2034. The market is expected to expand at a 44.5% CAGR between 2025 and 2034. Growth is driven by increased R&D investment, wider adoption of AI in radiology and cardiology, and rising demand for remote monitoring and personalized care. Software and machine learning currently lead the market, while deep learning and wearable devices are expected to grow fastest. North America remains the largest market, while Asia-Pacific is projected to see the strongest growth. Key challenges include regulatory complexity, high development costs, and data integration barriers. Overall, AI-enabled diagnostics and monitoring are positioned as central to the next phase of healthcare innovation.

Strategic Technology Impact

The Danaher–Masimo transaction reflects a broader shift in MedTech toward connected platforms rather than standalone devices. Healthcare providers are increasingly seeking integrated systems that combine diagnostics, monitoring, and analytics. By uniting Masimo’s sensing and monitoring technologies with Danaher’s diagnostics platforms, the company is positioning itself to support more scalable, data-driven care models across acute, chronic, and remote settings. This approach strengthens Danaher’s role in digital transformation efforts across healthcare systems.

Next Generation of Care

Philips highlights how AI is improving healthcare delivery for both clinicians and patients. AI reduces administrative workload by automating documentation and reporting, giving clinicians more time for patient care. It also speeds up medical imaging and improves image quality, making diagnostics faster and more accurate. AI supports less experienced staff through real-time guidance and automated measurements, helping standardize care. It enhances early disease detection by identifying patterns in medical images that may be missed manually. In addition, AI enables more personalized treatment by analyzing patient records and clinical notes, and supports predictive care by identifying risks earlier through data analysis and remote monitoring. Finally, AI empowers patients with personalized self-care tools and virtual assistants, while emphasizing the importance of privacy, ethics, and human oversight. Overall, the article positions AI as a tool that strengthens clinical workflows, improves outcomes, and supports more proactive healthcare.